ATE267594T1 - Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel - Google Patents

Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel

Info

Publication number
ATE267594T1
ATE267594T1 AT01110509T AT01110509T ATE267594T1 AT E267594 T1 ATE267594 T1 AT E267594T1 AT 01110509 T AT01110509 T AT 01110509T AT 01110509 T AT01110509 T AT 01110509T AT E267594 T1 ATE267594 T1 AT E267594T1
Authority
AT
Austria
Prior art keywords
medicinal product
solid tumors
album
production
treating solid
Prior art date
Application number
AT01110509T
Other languages
English (en)
Inventor
Marco Falciani
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Application granted granted Critical
Publication of ATE267594T1 publication Critical patent/ATE267594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01110509T 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel ATE267594T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (1)

Publication Number Publication Date
ATE267594T1 true ATE267594T1 (de) 2004-06-15

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01110509T ATE267594T1 (de) 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel

Country Status (22)

Country Link
US (1) US6652884B2 (de)
EP (1) EP1155692B1 (de)
JP (1) JP2001354559A (de)
KR (2) KR20010105248A (de)
CN (1) CN1198609C (de)
AT (1) ATE267594T1 (de)
AU (1) AU781517B2 (de)
BR (1) BR0102040A (de)
CA (1) CA2345482A1 (de)
DE (1) DE60103453T2 (de)
DK (1) DK1155692T3 (de)
ES (1) ES2221874T3 (de)
HU (1) HU229909B1 (de)
IL (1) IL142674A0 (de)
IT (1) ITMI20001107A1 (de)
MX (1) MXPA01004980A (de)
NO (1) NO330511B1 (de)
NZ (1) NZ511201A (de)
PT (1) PT1155692E (de)
RU (1) RU2270003C2 (de)
TR (1) TR200101353A3 (de)
ZA (1) ZA200103755B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP1585548B1 (de) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Zusammensetzungen, pharmakologisch wirksame agenzien enthaltend und wirkstofffreigabemethoden
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CA2626016A1 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
LT2481402T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
AU2014228386B2 (en) * 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
EP3313401B1 (de) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanopartikel mit sirolimus und einem albumin zur vewendung bei der behandlung von epitheloidzelltumoren
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
TWI660728B (zh) 2018-02-09 2019-06-01 National Chiao Tung University 胺基喹唑啉衍生物及其醫藥組合物與用途
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
CN120919082A (zh) * 2025-10-16 2025-11-11 天津医科大学总医院 一种负载蛋白药物的GelMA微球、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
JP3746293B2 (ja) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
ES2435944T3 (es) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
EP1100494A1 (de) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmazeutische zubereitung enthaltend eine wässrige lösung aus paclitaxel und albumin

Also Published As

Publication number Publication date
NO20012409L (no) 2001-11-19
CN1324613A (zh) 2001-12-05
PT1155692E (pt) 2004-09-30
ZA200103755B (en) 2001-11-15
ES2221874T3 (es) 2005-01-16
NO20012409D0 (no) 2001-05-16
KR20080091747A (ko) 2008-10-14
US6652884B2 (en) 2003-11-25
EP1155692A1 (de) 2001-11-21
US20010046961A1 (en) 2001-11-29
ITMI20001107A0 (it) 2000-05-18
CA2345482A1 (en) 2001-11-18
CN1198609C (zh) 2005-04-27
DE60103453T2 (de) 2005-06-23
ITMI20001107A1 (it) 2001-11-18
KR20010105248A (ko) 2001-11-28
BR0102040A (pt) 2002-03-19
MXPA01004980A (es) 2002-08-06
AU781517B2 (en) 2005-05-26
JP2001354559A (ja) 2001-12-25
NZ511201A (en) 2002-11-26
AU3876501A (en) 2001-11-22
TR200101353A2 (tr) 2001-12-21
HU0102039D0 (en) 2001-07-30
DE60103453D1 (de) 2004-07-01
DK1155692T3 (da) 2004-08-09
HUP0102039A2 (hu) 2002-05-29
IL142674A0 (en) 2002-03-10
HU229909B1 (en) 2014-12-29
HUP0102039A3 (en) 2002-12-28
TR200101353A3 (tr) 2001-12-21
NO330511B1 (no) 2011-05-09
HK1040368A1 (en) 2002-06-07
RU2270003C2 (ru) 2006-02-20
EP1155692B1 (de) 2004-05-26

Similar Documents

Publication Publication Date Title
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
CY1122659T1 (el) Ενωση 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτης για μη-νοηματικη καταστολη και τη θεραπεια ασθενειας
ATE533458T1 (de) Anlage zum automatischen herstellen von verpackungen für medizinische und/oder pharmazeutische und/oder nahrungsergänzende produkte
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
DE69921178D1 (de) Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit
ATE134507T1 (de) Mikroverkapseltes sonnenschutzmittel, das verfahren zur herstellung, kosmetische und pharmazeutische zubereitungen mit mikrokapseln und verwendung derselben
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
RU2001113688A (ru) Применение паклитаксела, стабилизированного альбумином, для изготовления лекарственного средства для лечения солидных опухолей и лекарственное средство, полученное указанным способом
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE396198T1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
DE60230869D1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE69029231D1 (de) Indolderivate, ihre herstellung und diese enthaltendes arzneimittel zum verhindern und behandeln von nephritis
DE60205894D1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid-derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
JP2005507888A5 (de)
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69620027D1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155692

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner